03/03/2021

MFN Drug Price Plan Frozen By U.S. Courts

Court injunctions have put the nail in the coffin of the Trump administration’s “Most Favored Nation” interim final rule aimed at lowering prescription drug prices, but experts say this probably isn’t the last we’ll see of international drug reference pricing.

The rule, which was set to take effect Jan. 1, proposed to restrict costs for the top 50 physician-administered Medicare Part B drugs—which account for almost 80% of Part B spending—to no more than the lowest price that drug manufacturers receive in other similar countries (bit.ly/3oMqlSv). Specifically, it would have replaced the existing average sales price plus 6% formula with a new one based on international pricing information from an index of 22 different countries.  READ MORE